for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Akeso Inc

9926.HK

Latest Trade

26.95HKD

Change

-0.95(-3.41%)

Volume

2,794,561

Today's Range

26.80

 - 

28.05

52 Week Range

25.70

 - 

69.90

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
27.90
Open
27.95
Volume
2,794,561
3M AVG Volume
91.43
Today's High
28.05
Today's Low
26.80
52 Week High
69.90
52 Week Low
25.70
Shares Out (MIL)
817.06
Market Cap (MIL)
22,795.89
Forward P/E
-23.86
Dividend (Yield %)
--

Next Event

Akeso Inc Annual Shareholders Meeting

Latest Developments

More

Akeso Says Ligufalimab Gets Approval From NMPA Of China

Akeso Says From Dec 10 2021 To Jan 5, Trustee Purchased Total Of About 2 Mln Shares On Market

Akeso Says Cadonilimab Combined With Concurrent Chemoradiotherapy Obtained Approval To Initiate Phase III Clinical Trial

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Akeso Inc

Akeso Inc is an investment holding company mainly engaged in the research and development of biological products. The Company is dedicated to addressing global unmet medical needs in oncology, immunology and other therapeutic areas. The Company's main products include AK104, AK105, AK112 and AK109. The Company conducts its businesses within the China market and to overseas markets.

Industry

Biotechnology & Drugs

Contact Info

No.6 Shennong Road

Huoju Development Zone

Zhongshan, GNG

528437

China

+86.760.89873936

http://www.akesobio.com/

Executive Leadership

Yu Xia

Executive Chairwoman of the Board, President, Chief Executive Officer

Xiaojie Xi

Chief Financial Officer, Joint Company Secretary

Baiyong Li

Senior Vice President, Chief Scientific Officer, Executive Director

Zhongmin Wang

Senior Vice President, Executive Director

Yu Xia

Senior Vice President, Executive Director

Key Stats

1.57 mean rating - 14 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2021(E)

0.4K
EPS (CNY)

2021(E)

-0.940
Price To Earnings (TTM)
--
Price To Sales (TTM)
144.44
Price To Book (MRQ)
4.81
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
11.73
LT Debt To Equity (MRQ)
11.38
Return on Investment (TTM)
-25.48
Return on Equity (TTM)
-22.60

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up